These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2726827)

  • 1. QSAR: quantitative structure-activity relationships in drug design. Proceedings of the 7th European Symposium on QSAR. Interlaken, Switzerland, September 5-9, 1988.
    Prog Clin Biol Res; 1989; 291():1-443. PubMed ID: 2726827
    [No Abstract]   [Full Text] [Related]  

  • 2. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
    Du QS; Huang RB; Wei YT; Pang ZW; Du LQ; Chou KC
    J Comput Chem; 2009 Jan; 30(2):295-304. PubMed ID: 18613071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 18th European symposium on quantitative structure-activity relationships.
    Tsantili-Kakoulidou A; Agrafiotis DK
    Expert Opin Drug Discov; 2011 Apr; 6(4):453-6. PubMed ID: 22646021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
    Du QS; Huang RB; Wei YT; Du LQ; Chou KC
    J Comput Chem; 2008 Jan; 29(2):211-9. PubMed ID: 17559075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR--a European viewpoint.
    Dearden JC
    Prog Clin Biol Res; 1989; 291():7-14. PubMed ID: 2657762
    [No Abstract]   [Full Text] [Related]  

  • 6. Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors.
    Mor M; Rivara S; Lodola A; Lorenzi S; Bordi F; Plazzi PV; Spadoni G; Bedini A; Duranti A; Tontini A; Tarzia G
    Chem Biodivers; 2005 Nov; 2(11):1438-51. PubMed ID: 17191945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
    Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
    Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Approaches to Drug Design: Quantitative Structure-Activity Relationships--13th European Symposium. 27 August-1 September 2000, Düsseldorf, Germany.
    Kubinyi H
    IDrugs; 2000 Nov; 3(11):1316-22. PubMed ID: 16047251
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening.
    Siraki AG; Chevaldina T; Moridani MY; O'Brien PJ
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):118-25. PubMed ID: 14982155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.
    Mente S; Gallaschun R; Schmidt A; Lebel L; Vanase-Frawley M; Fliri A
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6088-92. PubMed ID: 18948001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks.
    So SS; Karplus M
    J Med Chem; 1996 Mar; 39(7):1521-30. PubMed ID: 8691483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Pan D; Tseng Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(5):1591-607. PubMed ID: 14502494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A general method for exploiting QSAR models in lead optimization.
    Lewis RA
    J Med Chem; 2005 Mar; 48(5):1638-48. PubMed ID: 15743205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR design of novel antiepileptic sulfamides.
    Gavernet L; Dominguez Cabrera MJ; Bruno-Blanch LE; Estiú GL
    Bioorg Med Chem; 2007 Feb; 15(3):1556-67. PubMed ID: 17158052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible antineoplastic agents: Part XIII. Synthesis, biological evaluation and QSAR studies of some 1-(substituted benzenesulphonyl)-5-oxopyrrolidine-2-carboxylic acid derivatives.
    Purkayastha SK; Jha T; Pal DK; De AU
    Anticancer Drug Des; 1993 Apr; 8(2):95-100. PubMed ID: 8494605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonleast-squares jackknife regression in drug design.
    Mager PP
    Drug Des Deliv; 1991 Apr; 7(2):119-29. PubMed ID: 1910438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
    Kireev DB; Chrétien JR; Grierson DS; Monneret C
    J Med Chem; 1997 Dec; 40(26):4257-64. PubMed ID: 9435895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Three dimensional structure-activity relationships].
    Mátyus P; Borosy AP
    Acta Pharm Hung; 1998 Jan; 68(1):33-8. PubMed ID: 9528147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feature selection in quantitative structure-activity relationships.
    Walters WP; Goldman BB
    Curr Opin Drug Discov Devel; 2005 May; 8(3):329-33. PubMed ID: 15892248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional quantitative structure-activity relationship (3 D-QSAR) and docking studies on (benzothiazole-2-yl) acetonitrile derivatives as c-Jun N-terminal kinase-3 (JNK3) inhibitors.
    Shaikh AR; Ismael M; Del Carpio CA; Tsuboi H; Koyama M; Endou A; Kubo M; Broclawik E; Miyamoto A
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5917-25. PubMed ID: 16989998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.